![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institute of Biosciences and Technology, the Texas A&M University System Health Science Center, Houston, Texas (M.A., S.S.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
Cyclooxygenase 2 (COX-2) inhibitors, such as celecoxib (Cel), nimesulfide (NM), and NS-398 [NS; N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide] and other nonsteroidal anti-inflammatory drugs inhibit colon cancer growth and angiogenesis; however, the mechanism of this response is not well defined. Treatment of SW-480 colon cancer cells with Cel, NS, or NM decreased vascular endothelial growth factor (VEGF) mRNA and immunoreactive protein expression. This was also accompanied by decreased transactivation in cells transfected with constructs containing VEGF gene promoter inserts. Deletion analysis of the VEGF promoter indicated that decreased VEGF expression by COX-2 inhibitors was associated with the proximal -131 to -47 GC-rich region of the VEGF promoter that binds Sp proteins. Treatment of SW-480 cells with Cel, NM, and NS also decreased Sp1 and Sp4 protein expression but not that of Sp2 or Sp3. Similar results were observed in RKO, HT-29, and DLD colon cancer cells demonstrating comparable responses in COX-2-expressing and -nonexpressing colon cancer cell lines. COX-2 inhibitors do not affect Sp1 or Sp4 mRNA levels in SW-480 cells; however, decreased expression of both proteins was accompanied by increased protein ubiquitination and inhibited by the proteasome inhibitor gliotoxin. These results suggest that the antiangiogenic activity of COX-2 inhibitors in colon cancer cells is linked to activation of proteasome-dependent degradation of Sp1 and Sp4 proteins.
Address correspondence to: Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, Vet. Res. Bldg. 409, College Station, TX 77843-4466. E-mail: ssafe{at}cvm.tamu.edu
This article has been cited by other articles:
|
|
 |
|
  S. Papineni, S. Chintharlapalli, M. Abdelrahim, S.-o. Lee, R. Burghardt, A. Abudayyeh, C. Baker, L. Herrera, and S. Safe Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met Carcinogenesis, July 1, 2009; 30(7): 1193 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Kanies, J. J. Smith, C. Kis, C. Schmidt, S. Levy, K. S.A. Khabar, J. Morrow, N. Deane, D. A. Dixon, and R. D. Beauchamp Oncogenic Ras and Transforming Growth Factor-{beta} Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition Mol. Cancer Res., July 1, 2008; 6(7): 1124 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Wu, J.-C. Lin, S.-C. Yang, C.-W. Lin, J. J.W. Chen, J.-Y. Shih, T.-M. Hong, and P.-C. Yang Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBP{alpha} Mol. Cancer Ther., June 1, 2008; 7(6): 1365 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Chuang, Y.-T. Wang, S.-H. Yeh, Y.-W. Liu, W.-C. Chang, and J.-J. Hung Phosphorylation by c-Jun NH2-terminal Kinase 1 Regulates the Stability of Transcription Factor Sp1 during Mitosis Mol. Biol. Cell, March 1, 2008; 19(3): 1139 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Finetti, R. Solito, L. Morbidelli, A. Giachetti, M. Ziche, and S. Donnini Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1 J. Biol. Chem., January 25, 2008; 283(4): 2139 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Mertens-Talcott, S. Chintharlapalli, X. Li, and S. Safe The Oncogenic microRNA-27a Targets Genes That Regulate Specificity Protein Transcription Factors and the G2-M Checkpoint in MDA-MB-231 Breast Cancer Cells Cancer Res., November 15, 2007; 67(22): 11001 - 11011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S. D. Cho, K. Yoon, and S. Safe Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4 in Pancreatic Cancer Cells Cancer Res., April 1, 2007; 67(7): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chintharlapalli, S. Papineni, S. K. Ramaiah, and S. Safe Betulinic Acid Inhibits Prostate Cancer Growth through Inhibition of Specificity Protein Transcription Factors Cancer Res., March 15, 2007; 67(6): 2816 - 2823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Borthwick, A. S. Johnson, M. Partington, J. Burn, R. Wilson, and H. M. Arthur Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism FASEB J, October 1, 2006; 20(12): 2009 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Slomiany and S. A. Rosenzweig Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 666 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
